Remifentanil Pharmacology

Quick Answer

Remifentanil is a synthetic ultra-short-acting mu-opioid agonist distinguished by its unique ester linkage that allows rapid hydrolysis by non-specific tissue and plasma esterases, resulting in organ-independent metabolism and a context-insensitive half-time of 3-4 minutes regardless of infusion duration. With the highest mu-receptor selectivity among clinically used opioids (mu:kappa:delta ratio approximately 200:1:1), remifentanil produces profound analgesia, respiratory depression, and bradycardia with minimal histamine release. Its pharmacokinetics follow a three-compartment model with rapid onset (blood-brain equilibration t1/2keo 1.0-1.5 minutes), small volume of distribution (0.35 L/kg at steady state), and extremely high clearance (40-60 mL/kg/min) via ester hydrolysis to the inactive carboxylic acid metabolite remifentanil acid (GI-90291). Clinical applications include total intravenous anaesthesia (TIVA), neurosurgery, cardiac surgery, and sedation in high-risk patients, though important considerations include opioid-induced hyperalgesia (OIH), acute tolerance development, and the need for transitional analgesia prior to emergence. [1-8]

Pharmacology Overview

Chemical Classification and Structure

Remifentanil (Ultiva) is a synthetic phenylpiperidine opioid agonist that was first introduced into clinical practice in 1996, representing a significant pharmacokinetic advancement in opioid pharmacology. Its chemical structure is 3-[4-methoxycarbonyl-4-[(1-oxopropyl)phenylamino]-1-piperidine]propanoic acid methyl ester, with molecular formula C20H28N2O5 and molecular weight 376.5 Da. The distinguishing structural feature is the presence of a methyl ester linkage on the propanoic acid side chain, which serves as the substrate for ester hydrolysis by non-specific esterases. This ester bond is crucial to remifentanil's unique pharmacokinetic profile, allowing rapid metabolism that is independent of hepatic or renal function. Unlike fentanyl and its congeners (alfentanil, sufentanil), which undergo hepatic cytochrome P450-mediated metabolism, remifentanil's ester linkage renders it susceptible to hydrolysis by ubiquitous tissue and plasma esterases. The drug is formulated as a lyophilized powder containing glycine as a buffer and requires reconstitution before administration. The glycine content precludes neuraxial administration due to potential neurotoxicity from the glycine vehicle. [9-14]

Molecular Mechanism of Action

Remifentanil exerts its pharmacological effects primarily through agonist activity at the mu (mu) opioid receptor, a G protein-coupled receptor (GPCR) belonging to the rhodopsin family. Remifentanil demonstrates the highest mu-receptor selectivity among clinically used opioids, with a selectivity ratio of approximately 200:1:1 (mu:kappa:delta). Binding to the mu-receptor activates inhibitory Gi/Go proteins, leading to multiple intracellular effects: inhibition of adenylyl cyclase reducing cyclic AMP (cAMP) production; activation of inwardly rectifying potassium channels (GIRK) causing membrane hyperpolarization; and inhibition of voltage-gated calcium channels reducing neurotransmitter release. These mechanisms collectively reduce neuronal excitability and neurotransmission in pain pathways. At the spinal cord level, mu-receptor activation in the dorsal horn inhibits substance P and glutamate release from primary afferent C-fiber terminals, reducing nociceptive transmission. Supraspinally, mu-receptors in the periaqueductal gray, rostral ventromedial medulla, and thalamus modulate descending pain inhibition and affective components of pain perception. The mu-receptor is also expressed in the respiratory centers (pre-Botzinger complex), chemoreceptor trigger zone, and gastrointestinal tract, explaining the respiratory depression, nausea, and reduced gastrointestinal motility associated with opioid agonists. [15-22]

Ester Linkage and Metabolism

The defining pharmacological characteristic of remifentanil is its metabolism by non-specific tissue and plasma esterases, which hydrolyze the methyl ester linkage to produce the inactive carboxylic acid metabolite remifentanil acid (GI-90291). These esterases are distinct from plasma cholinesterase (pseudocholinesterase) and red blood cell acetylcholinesterase, and their activity is not affected by anticholinesterase drugs or inherited cholinesterase deficiencies. The esterases responsible for remifentanil hydrolysis are widely distributed throughout the body, including blood, skeletal muscle, intestinal mucosa, and virtually all tissues except the central nervous system. This ubiquitous distribution ensures consistent metabolism regardless of organ function, making remifentanil's pharmacokinetics predictable even in patients with hepatic or renal impairment. The half-life of the ester hydrolysis reaction is approximately 3-4 minutes, and this reaction proceeds at a constant rate independent of plasma concentration (first-order kinetics) until very high concentrations are achieved. The metabolite GI-90291 has minimal opioid activity (approximately 1/4600th the potency of remifentanil at mu-receptors) and is renally excreted, but accumulation in renal failure does not cause clinically significant effects. [23-30]

Pharmacokinetic Principles

Absorption and Distribution

Remifentanil is administered exclusively by intravenous injection due to its rapid ester hydrolysis preventing oral bioavailability and its formulation with glycine precluding neuraxial administration. Following intravenous bolus, remifentanil demonstrates extremely rapid onset of effect with blood-brain equilibration half-time (t1/2keo) of 1.0-1.5 minutes, allowing peak effect within 60-90 seconds. This rapid equilibration is attributable to remifentanil's moderate lipophilicity (octanol:water partition coefficient approximately 17.9 at pH 7.4), small molecular size, and high unionized fraction at physiological pH (approximately 58% at pH 7.4, pKa 7.07). The volume of distribution follows a three-compartment model with central compartment volume (Vc) of approximately 0.1 L/kg, steady-state volume of distribution (Vdss) of 0.35 L/kg (range 0.25-0.50 L/kg), and peripheral compartment volumes reflecting distribution to less perfused tissues. The relatively small Vdss compared to fentanyl (4.0 L/kg) and sufentanil (1.7 L/kg) reflects remifentanil's rapid metabolism limiting tissue accumulation. Approximately 70% of remifentanil is protein-bound, primarily to alpha-1-acid glycoprotein, with protein binding being concentration-independent over the clinical range. [31-38]

Context-Insensitive Half-Time

The context-sensitive half-time (CSHT) describes the time required for plasma concentration to decrease by 50% after termination of an infusion of a given duration. For remifentanil, the CSHT is approximately 3-4 minutes and remains constant regardless of infusion duration, earning the descriptor "context-insensitive." This unique property distinguishes remifentanil from all other opioids and most intravenous anesthetics. The context-insensitivity results from remifentanil's rapid ester hydrolysis, which clears the drug faster than it can redistribute from peripheral compartments. In contrast, fentanyl demonstrates a CSHT that increases from 20 minutes after a 2-hour infusion to over 300 minutes after an 8-hour infusion, while alfentanil's CSHT increases from 15 minutes to 60 minutes over the same duration. Sufentanil has intermediate behavior with CSHT increasing from 15 to 35 minutes. The clinical implication is that remifentanil provides predictable, rapid recovery from opioid effect regardless of the duration of administration, making it ideal for procedures of unpredictable length or when rapid emergence is desired. However, this same property necessitates early transition to longer-acting analgesics to prevent inadequate postoperative pain control. [39-46]

Metabolism and Elimination

Remifentanil undergoes rapid hydrolysis by non-specific tissue and plasma esterases to the primary metabolite remifentanil acid (GI-90291), which accounts for approximately 95% of drug elimination. A minor metabolic pathway involves N-dealkylation to GI-94219, contributing less than 5% of total clearance. The total body clearance of remifentanil is exceptionally high at 40-60 mL/kg/min (approximately 2,400-3,600 mL/min for a 60 kg patient), exceeding hepatic blood flow by a factor of 2-3 and confirming the predominance of extrahepatic clearance mechanisms. The elimination half-life (t1/2beta) is 10-20 minutes, though this is clinically less relevant than the CSHT due to the rapid decline in effect-site concentration after infusion cessation. The metabolite GI-90291 has negligible mu-opioid activity (mu-receptor affinity approximately 1/4600th that of remifentanil) and is eliminated renally with a half-life of approximately 90-130 minutes. In patients with severe renal impairment, GI-90291 accumulates but does not produce clinically significant opioid effects, allowing remifentanil to be used without dose adjustment in renal failure. Similarly, hepatic impairment does not significantly alter remifentanil pharmacokinetics due to the extrahepatic metabolism. [47-54]

Special Population Pharmacokinetics

Elderly patients demonstrate approximately 25-50% reduction in remifentanil clearance and increased sensitivity, requiring dose reduction of 30-50%. The volume of distribution is also reduced in elderly patients. Obese patients present pharmacokinetic challenges; remifentanil dosing should be based on ideal body weight (IBW) or lean body mass rather than total body weight due to the poor distribution into adipose tissue and unchanged clearance per lean mass. Studies demonstrate that using total body weight results in excessive dosing and prolonged respiratory depression. Pediatric patients have higher clearance rates (50-80% greater than adults) and larger central compartment volumes, requiring higher weight-based dosing. Neonates and infants less than 2 months of age demonstrate 2-3 fold higher volumes of distribution and similar or slightly lower clearance, but the CSHT remains short. Critically ill patients may have altered protein binding due to changes in alpha-1-acid glycoprotein concentrations, but the clinical significance is minimal given remifentanil's rapid metabolism. Pregnant patients demonstrate modestly increased clearance (15-30%) during the third trimester, though dose adjustments are generally not required. [55-62]

Unique Properties

Organ-Independent Metabolism

The most clinically significant pharmacokinetic property of remifentanil is its organ-independent metabolism via tissue esterases. Unlike fentanyl (hepatic CYP3A4), morphine (hepatic UGT2B7), and alfentanil (hepatic CYP3A4), remifentanil's clearance is unaffected by hepatic dysfunction of any severity. Studies in patients with severe liver disease (Child-Pugh C cirrhosis) demonstrate no significant changes in remifentanil clearance or elimination half-life compared to healthy controls. Similarly, remifentanil pharmacokinetics are unchanged in patients with renal failure, including those on hemodialysis. While the inactive metabolite GI-90291 accumulates in renal impairment (half-life increases from 90 minutes to 30 hours), it produces no clinically significant opioid effects due to its negligible receptor affinity. This organ-independent metabolism provides several clinical advantages: predictable pharmacokinetics in multi-organ failure; suitability for patients with hepatorenal syndrome; consistent effect-site targeting in patients with variable hepatic function during liver transplantation; and reliable emergence timing in patients with chronic organ dysfunction. These properties make remifentanil the opioid of choice when hepatic or renal function is compromised or uncertain. [63-70]

No Prolonged Duration in Organ Failure

The clinical consequence of organ-independent metabolism is that remifentanil infusions do not result in prolonged duration of effect in patients with hepatic or renal failure. This contrasts sharply with morphine, where the active metabolite morphine-6-glucuronide (M6G) accumulates in renal failure causing prolonged sedation and respiratory depression. Fentanyl and alfentanil demonstrate prolonged elimination half-lives in hepatic impairment, leading to unpredictable recovery. For remifentanil, the context-sensitive half-time of 3-4 minutes is maintained regardless of organ function, providing reliable and predictable offset of opioid effect. In critically ill patients with multi-organ dysfunction, this predictability allows accurate neurological assessment after infusion cessation (typically complete resolution of opioid effects within 15-20 minutes). The absence of active metabolites and the organ-independent clearance make remifentanil particularly valuable in the intensive care setting for daily sedation interruption protocols and neurological assessment windows. [71-76]

Rapid Offset and Emergence

The ultrashort duration of action provides distinct advantages for procedures requiring rapid emergence and early neurological assessment. After discontinuation of a remifentanil infusion at analgesic concentrations (1-4 ng/mL), plasma concentrations decrease by 50% within 3-4 minutes and by 80% within 10-15 minutes. Return of spontaneous ventilation typically occurs within 3-5 minutes of cessation, with complete recovery of respiratory function within 10-15 minutes. This rapid offset allows extubation within minutes of completing surgery, reducing operating room time and facilitating early recovery room discharge. In neurosurgical procedures, the rapid emergence permits immediate neurological examination to detect early complications. In cardiac surgery, remifentanil allows early extubation ("fast-track" cardiac anaesthesia) within 2-6 hours postoperatively, reducing ICU length of stay. However, the rapid offset requires careful planning for transitional analgesia; without pre-emptive administration of longer-acting opioids or multimodal analgesia, patients may experience severe pain upon emergence. The window for administering transitional analgesia is narrow, typically 20-30 minutes before anticipated emergence. [77-84]

Clinical Applications

Total Intravenous Anaesthesia (TIVA)

Remifentanil is a cornerstone agent for total intravenous anaesthesia, typically combined with propofol for induction and maintenance without volatile anesthetics. The combination provides excellent hemodynamic stability, rapid titration to surgical stimulation, antiemetic benefits (avoiding volatile agent-induced PONV), and predictable emergence. Target-controlled infusion (TCI) systems using validated pharmacokinetic models (Minto model for remifentanil, Marsh or Schnider for propofol) enable precise effect-site targeting. Typical effect-site concentrations for remifentanil during TIVA range from 2-8 ng/mL, with higher concentrations (4-8 ng/mL) for painful surgical stimulation and lower concentrations (1-3 ng/mL) during less stimulating phases. The propofol-remifentanil combination demonstrates synergistic interaction for hypnosis and immobility, allowing significant dose reduction of both agents compared to monotherapy. A typical TIVA protocol might target remifentanil Ce 3-4 ng/mL with propofol Ce 3-4 mcg/mL, adjusted based on clinical response and processed EEG monitoring (BIS 40-60). The analgesic:hypnotic synergy and context-insensitive offset make this combination ideal for day surgery, neurosurgery, and procedures requiring rapid emergence. [85-92]

High-Risk Patients

Remifentanil's pharmacokinetic profile makes it particularly suited for anaesthesia in high-risk patient populations. In patients with hepatic dysfunction (cirrhosis, liver transplantation), remifentanil provides predictable kinetics without accumulation or prolonged effect. During liver transplantation, the anhepatic phase does not significantly alter remifentanil pharmacokinetics, allowing continuous administration throughout the procedure with reliable emergence. In patients with renal failure, remifentanil avoids the accumulation of active metabolites that complicates morphine and fentanyl use. For morbidly obese patients, dosing based on ideal body weight provides consistent effect with predictable emergence, unlike lipophilic opioids that accumulate in adipose tissue. In elderly patients, while dose reduction is required due to decreased clearance, the CSHT remains short, providing reliable offset. For patients with cardiac dysfunction, remifentanil's titratable effect allows rapid adjustment to hemodynamic changes, and the combination with low-dose propofol minimizes cardiovascular depression compared to volatile-based techniques. In critically ill ICU patients, remifentanil infusions allow daily sedation interruption for neurological assessment without prolonged residual effects. [93-100]

Neurosurgery and Cardiac Surgery

Remifentanil has become a preferred opioid for neurosurgical procedures requiring intraoperative neurological monitoring or early postoperative neurological assessment. The rapid offset permits immediate awakening for assessment of motor function, speech, and cognitive status. For awake craniotomy procedures, remifentanil infusion (0.05-0.1 mcg/kg/min) combined with scalp nerve blocks provides analgesia while maintaining patient cooperation for cortical mapping. The absence of accumulation allows precise timing of emergence regardless of procedure duration. In cardiac surgery, remifentanil-based anaesthesia facilitates "fast-track" protocols with early extubation (2-6 hours postoperatively) compared to high-dose fentanyl techniques (12-24 hours to extubation). Meta-analyses demonstrate that remifentanil-based cardiac anaesthesia reduces time to extubation by 4-8 hours compared to fentanyl or sufentanil-based techniques without increasing perioperative myocardial ischemia or mortality. The hemodynamic stability of remifentanil at analgesic doses (minimal histamine release, modest bradycardia) is advantageous in patients with coronary artery disease, though profound bradycardia may require atropine or pacing in susceptible patients. [101-108]

Remifentanil-Based Anaesthesia

"Remifentanil-based anaesthesia" refers to techniques where remifentanil provides the primary anesthetic component, with minimal or no volatile anesthetic. High-dose remifentanil (0.3-0.5 mcg/kg/min, effect-site concentration 8-15 ng/mL) combined with a hypnotic agent (propofol or low-dose volatile) produces profound anesthesia with suppression of surgical stress response. The high mu-opioid receptor occupancy blunts sympathetic responses to surgical stimulation, maintaining hemodynamic stability. However, this approach requires careful consideration of opioid-induced hyperalgesia and tolerance. Studies suggest that high-dose remifentanil infusions (cumulative dose >30 mcg/kg) may increase postoperative pain scores and opioid consumption compared to lower doses combined with multimodal analgesia. The technique is most appropriate for procedures where rapid, complete emergence is paramount and where multimodal analgesia can be established prior to emergence. Alternative "opioid-sparing" approaches using regional anesthesia, ketamine, dexmedetomidine, or lidocaine infusions may reduce the reliance on high-dose remifentanil while maintaining its pharmacokinetic advantages. [109-116]

Considerations

Opioid-Induced Hyperalgesia (OIH)

Opioid-induced hyperalgesia (OIH) is a paradoxical increase in pain sensitivity following opioid exposure, distinct from tolerance (which reflects decreased opioid effect at constant receptor occupancy). Remifentanil has been particularly associated with OIH due to its rapid receptor kinetics and high receptor affinity. The proposed mechanisms include: NMDA receptor activation via mu-opioid receptor-NMDA receptor crosstalk; spinal dynorphin release promoting kappa-opioid mediated pronociception; enhanced descending facilitation from the rostral ventromedial medulla; and central sensitization through neuroplastic changes in dorsal horn neurons. Clinical evidence suggests that higher remifentanil doses (>0.2 mcg/kg/min) and longer infusion durations increase the risk of OIH, manifesting as increased postoperative pain scores, greater analgesic requirements, and enhanced sensitivity to mechanical stimuli. The incidence of clinically significant OIH varies widely in studies (10-50%) depending on definitions and patient populations. Strategies to mitigate OIH include: using the lowest effective remifentanil dose; co-administration of NMDA antagonists (ketamine 0.1-0.25 mg/kg bolus, 2-4 mcg/kg/min infusion); multimodal analgesia with non-opioid agents; regional anesthesia; and gradual rather than abrupt remifentanil discontinuation. [117-124]

Acute Tolerance Development

Acute opioid tolerance refers to the decrease in opioid effect with repeated or continuous exposure over a short timeframe (hours to days), requiring dose escalation to maintain effect. Remifentanil demonstrates more rapid tolerance development than longer-acting opioids, likely related to its rapid receptor kinetics and high mu-receptor occupancy. The mechanisms overlap with OIH and include: receptor desensitization via GRK (G protein-coupled receptor kinase) phosphorylation; receptor internalization and downregulation; cAMP superactivation (adenylyl cyclase upregulation); and activation of pronociceptive systems. Clinical studies demonstrate that patients receiving higher remifentanil doses intraoperatively require higher opioid doses postoperatively, though separating tolerance from OIH effects is methodologically challenging. The clinical implication is that remifentanil dose requirements may increase during prolonged infusions, and postoperative opioid requirements may exceed expectations based on pre-operative opioid use. Strategies to manage tolerance include: opioid rotation to agents with different receptor kinetics; NMDA antagonist co-administration; alpha-2 agonists (dexmedetomidine, clonidine); and early implementation of non-opioid multimodal analgesia. [125-132]

Transition to Long-Acting Opioids

The rapid offset of remifentanil necessitates careful planning for transitional analgesia to prevent inadequate postoperative pain control. Strategies for opioid transition include:

Pre-emptive administration: Longer-acting opioids (morphine 0.1-0.15 mg/kg, fentanyl 1-2 mcg/kg, or oxycodone 0.1 mg/kg) should be administered 20-40 minutes before anticipated emergence while remifentanil is still providing analgesia. This allows time for the longer-acting opioid to reach effect-site concentration before remifentanil effect dissipates.

Multimodal analgesia: Administration of paracetamol, NSAIDs, and regional anesthesia/local anesthetic infiltration reduces opioid requirements and improves analgesia quality. Gabapentinoids (pregabalin 75-150 mg, gabapentin 300-600 mg) administered preoperatively may reduce both pain and opioid consumption.

Gradual weaning: Rather than abrupt discontinuation, gradually reducing remifentanil infusion rate over 20-30 minutes while initiating alternative analgesia may reduce the risk of OIH and acute tolerance-related hyperalgesia.

Patient-controlled analgesia (PCA): Transitioning to morphine or fentanyl PCA allows patient-driven dose titration during the period when analgesic requirements may be elevated due to remifentanil-induced hyperalgesia. [133-140]

ANZCA Primary Exam Focus

Common MCQ Patterns

ANZCA Primary MCQs frequently test remifentanil's unique pharmacokinetic properties, particularly the context-insensitive half-time (3-4 minutes constant regardless of infusion duration) and ester metabolism by tissue esterases (NOT plasma cholinesterase). Questions differentiate remifentanil from other opioids based on metabolism pathway (ester hydrolysis vs. hepatic CYP450) and resulting independence from organ function. The structure-activity relationship emphasizing the ester linkage and its metabolic consequences is commonly tested. Pharmacokinetic parameters including volume of distribution (0.35 L/kg), clearance (40-60 mL/kg/min), and t1/2keo (1.0-1.5 minutes) may appear in calculation questions. Questions comparing opioid receptor selectivity often require knowledge that remifentanil has the highest mu-selectivity among clinical opioids. Drug interactions with propofol (synergistic interaction for hypnosis) and the hemodynamic effects (bradycardia, minimal histamine release) are commonly examined. [141-148]

Primary Viva Question Themes

Primary vivas typically begin with mechanism of action and progress to clinical applications. Examiners commonly ask about mu-opioid receptor signaling pathways (Gi protein, adenylyl cyclase inhibition, GIRK channel activation, calcium channel inhibition) and how these produce analgesia. The unique ester metabolism is extensively explored, including comparison with plasma cholinesterase (different enzyme systems), effects of anticholinesterases (none on remifentanil metabolism), and behavior in hepatic/renal failure (unchanged kinetics). Context-sensitive half-time concept requires graphical explanation comparing remifentanil with fentanyl, alfentanil, and sufentanil. Clinical scenario questions explore dosing for TIVA, management of emergence, OIH prevention strategies, and transitional analgesia planning. Candidates should be prepared to discuss advantages and disadvantages of remifentanil in specific populations (elderly, obese, hepatorenal failure) and for specific procedures (neurosurgery, cardiac surgery, day surgery). [149-156]

Calculation Questions

Common calculations include: determining infusion rates in mcg/kg/min from TCI target concentrations; calculating weight-based dosing for specific patient populations (using IBW for obese patients); predicting emergence timing based on CSHT; and comparing doses between patients of different weights. Sample calculation: For a 70 kg patient, calculate the infusion rate (mL/hr) to deliver remifentanil 0.15 mcg/kg/min using a solution of 1 mg/mL. Answer: 0.15 mcg/kg/min x 70 kg = 10.5 mcg/min = 630 mcg/hr = 0.63 mg/hr = 0.63 mL/hr. Candidates should also understand the relationship between bolus dose and infusion rate for maintaining steady-state concentrations, and the time constants for effect-site equilibration. [157-162]

Australian/NZ Specific Considerations

TGA-Approved Formulations

The Therapeutic Goods Administration (TGA) has approved remifentanil (as the hydrochloride salt) in lyophilized powder form requiring reconstitution. Available presentations include 1 mg, 2 mg, and 5 mg vials. The formulation contains glycine as a buffer/excipient, which precludes neuraxial (epidural or intrathecal) administration due to potential glycine-induced neurotoxicity. Reconstitution is typically performed with sterile water, 0.9% sodium chloride, or 5% dextrose to a concentration of 1 mg/mL for bolus administration or further diluted to 20-50 mcg/mL for infusion. The reconstituted solution is stable for 24 hours at room temperature. Strict aseptic technique is required during reconstitution and administration. TGA mandates that remifentanil administration occurs only in settings with full resuscitation facilities, continuous monitoring, and personnel trained in airway management. [163-170]

PBS Listing and Australian Brand Names

Remifentanil is available in Australia under the brand name Ultiva (Aspen Pharmacare), with generic equivalents becoming available. It is listed on the Pharmaceutical Benefits Scheme (PBS) as a Schedule 8 (Controlled Drug) with restrictions limiting use to hospital settings. The PBS listing requires that remifentanil be administered by or under the supervision of an anaesthetist or intensivist in an appropriate clinical environment. Hospital pharmacy departments procure remifentanil through standard pharmaceutical supply chains, with individual patient scripts not typically generated. In New Zealand, remifentanil is funded through PHARMAC and available via hospital pharmaceutical budgets. Cost considerations vary between institutions based on procurement contracts. The lyophilized formulation has a shelf life of 2-3 years when stored below 25 degrees C and protected from light. [171-178]

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Considerations

Limited pharmacogenomic data exists specifically for Aboriginal and Torres Strait Islander populations regarding opioid metabolism and response. However, several clinical considerations are relevant for remifentanil administration in Indigenous patients. Higher rates of chronic disease, including diabetes and cardiovascular disease, may influence anesthetic management but have minimal impact on remifentanil pharmacokinetics given its organ-independent metabolism. Remote and rural Indigenous communities face challenges accessing tertiary surgical services, often requiring extended travel and separation from family and community support systems. Pre-operative cultural assessment should identify specific requirements including presence of family members, cultural liaison involvement, and any traditional healing practices. Pain expression varies across cultures, and post-operative pain assessment tools validated in Indigenous populations should be used where available. The rapid offset of remifentanil necessitates careful transitional analgesia planning, which may be complicated in remote facilities with limited analgesic options or pain service support.

Maori Health Considerations (New Zealand)

For Maori patients, whanau (family) involvement in healthcare decisions reflects the collective nature of Maori culture. Tikanga (cultural protocols) should be respected throughout the perioperative period. The concept of mauri (life force) and its preservation through surgical intervention may require explanation in culturally appropriate terms. Maori patients may express pain differently, and culturally safe assessment approaches should be employed. Access to specialist anaesthesia services varies across New Zealand, with some rural Maori communities requiring significant travel for surgical procedures. Health equity considerations include ensuring that the benefits of modern anaesthetic techniques, including remifentanil-based TIVA with rapid emergence, are equitably available to Maori patients regardless of geographic location. [179-186]

Adverse Effects and Complications

Respiratory Depression

Remifentanil causes profound, dose-dependent respiratory depression through direct action on brainstem respiratory centers, including the pre-Botzinger complex and nucleus tractus solitarius. At analgesic concentrations (1-4 ng/mL), minute ventilation decreases by 30-50%, with reduced tidal volume and respiratory rate. At higher concentrations (4-8 ng/mL), apnea commonly occurs and assisted ventilation is required. The respiratory depression is rapidly reversible with discontinuation due to remifentanil's short context-sensitive half-time; spontaneous ventilation typically returns within 3-5 minutes. Naloxone (0.1-0.4 mg IV) can rapidly reverse respiratory depression but also reverses analgesia. The brief duration of remifentanil effect often makes naloxone unnecessary if ventilatory support can be provided temporarily.

Bradycardia and Hypotension

Remifentanil causes vagally-mediated bradycardia through direct action on cardiac mu-opioid receptors and brainstem vagal nuclei. The incidence of clinically significant bradycardia (HR <45 bpm) is approximately 5-15% with bolus administration and is increased by concomitant beta-blocker therapy. Profound bradycardia may occur with rapid bolus injection, particularly during induction when combined with propofol. Treatment includes atropine (0.4-0.6 mg IV), glycopyrrolate (0.2-0.4 mg IV), or reducing remifentanil infusion rate. Hypotension is less common than with other opioids due to minimal histamine release but may occur secondary to bradycardia, reduced sympathetic tone, or synergy with propofol. Pre-treatment with anticholinergics is not routinely recommended but may be considered in patients at high risk for bradycardia.

Muscle Rigidity

Rapid bolus injection of remifentanil, particularly at high doses (>2 mcg/kg), can cause truncal and chest wall rigidity ("wooden chest syndrome"), impairing ventilation. The mechanism involves mu-opioid receptor activation in the striatum and spinal cord, causing increased muscle tone. Prevention involves slow bolus administration (over 30-60 seconds) or infusion-only techniques. Treatment of established rigidity includes neuromuscular blocking agents (succinylcholine or non-depolarizing agents), which permit ventilation and intubation. Naloxone can reverse rigidity but also reverses analgesia. [187-194]

Assessment Content

SAQ Practice Question 1 (20 marks)

Question: Compare and contrast the pharmacokinetics of remifentanil and fentanyl. Explain how these differences influence clinical decision-making for a 75 kg, 65-year-old patient undergoing a 4-hour neurosurgical procedure requiring rapid emergence for neurological assessment.

Model Answer:

Pharmacokinetic comparison: [8 marks]

[2 marks for correct values in at least 4 parameters]

Key differences: [3 marks]

• Remifentanil CSHT is constant regardless of duration; fentanyl CSHT increases progressively [1]
• Remifentanil clearance exceeds hepatic blood flow (extrahepatic metabolism); fentanyl depends on hepatic function [1]
• Remifentanil's small Vdss limits tissue accumulation; fentanyl accumulates in fat and muscle [1]

Clinical decision-making for this case: [9 marks]

For rapid emergence requirement: [3 marks]

• Remifentanil preferred due to constant CSHT of 3-4 minutes regardless of 4-hour infusion
• Patient will be awake and assessable within 10-15 minutes of stopping remifentanil
• Fentanyl CSHT after 4 hours would be ~260 minutes, delaying neurological assessment by hours

Elderly patient considerations: [2 marks]

• Both opioids require dose reduction (25-50%) in elderly
• Remifentanil clearance decreased 25-50% but CSHT unchanged
• Fentanyl clearance may be more variably affected

Transitional analgesia planning: [3 marks]

• Remifentanil's rapid offset necessitates early transition to long-acting analgesia
• Morphine 0.1-0.15 mg/kg or oxycodone should be given 20-30 minutes before emergence
• Multimodal analgesia (paracetamol, scalp block) should be established

OIH considerations: [1 mark]

• 4-hour remifentanil infusion increases OIH risk; consider NMDA antagonist (ketamine) co-administration

Total: 20 marks

---

SAQ Practice Question 2 (20 marks)

Question: A 55-year-old, 90 kg man with Child-Pugh C cirrhosis and chronic kidney disease (eGFR 18 mL/min) requires anesthesia for a transjugular intrahepatic portosystemic shunt (TIPS) procedure. Discuss the pharmacology of remifentanil that makes it suitable for this patient, including mechanism, metabolism, and dosing considerations.

Model Answer:

Why remifentanil is suitable: [4 marks]

• Organ-independent metabolism via tissue esterases [1]
• Unchanged pharmacokinetics in hepatic failure [1]
• Unchanged pharmacokinetics in renal failure [1]
• Inactive metabolite (GI-90291) even if accumulated [1]

Mechanism of action: [4 marks]

• Mu-opioid receptor agonist with highest mu-selectivity (200:1:1 mu:kappa:delta) [1]
• Gi protein activation, adenylyl cyclase inhibition [1]
• GIRK channel activation (K+ efflux), Ca2+ channel inhibition [1]
• Spinal and supraspinal analgesia, respiratory depression, bradycardia [1]

Metabolism pathway: [4 marks]

• Ester hydrolysis by non-specific tissue and plasma esterases [1]
• Esterases distinct from plasma cholinesterase (not affected by anticholinesterases or genetic variants) [1]
• Primary metabolite GI-90291 has 1/4600th mu-receptor affinity [1]
• GI-90291 renally excreted but accumulation clinically insignificant [1]

Pharmacokinetic parameters in organ failure: [4 marks]

• Clearance maintained at 40-60 mL/kg/min regardless of liver function [1]
• CSHT remains 3-4 minutes in hepatorenal syndrome [1]
• No prolongation of effect despite anhepatic/anuric states [1]
• Compare to morphine (M6G accumulation) and fentanyl (reduced clearance) [1]

Dosing considerations: [4 marks]

• Standard loading and infusion rates appropriate (no adjustment for organ failure) [1]
• Dose may need reduction for frailty/debility common in ESLD (start conservatively) [1]
• Monitor for bradycardia (beta-blocker use common in cirrhosis) [1]
• Plan transitional analgesia avoiding morphine (use fentanyl PCA or oxycodone) [1]

Total: 20 marks

---

Primary Viva Scenario (15 marks)

Examiner: You are asked to provide anesthesia for a 45-year-old woman undergoing laparoscopic cholecystectomy as a day case. She is otherwise healthy but is very anxious about postoperative pain based on a previous experience. Discuss your approach to opioid selection for this case.

Candidate:

Initial considerations: [3 marks]

• Day surgery requires rapid emergence and early discharge [1]
• Patient anxiety about pain suggests need for reliable analgesia plan [1]
• Laparoscopic cholecystectomy: moderate surgical stimulus, typically 45-90 minutes [1]

Opioid options and comparison: [4 marks]

"For this day surgery case, I would consider remifentanil-based TIVA versus conventional fentanyl-based technique."

Remifentanil advantages:

• Context-insensitive half-time (3-4 min) provides predictable rapid emergence [1]
• Ideal for TIVA with propofol, reducing PONV versus volatile techniques [1]

Remifentanil disadvantages:

• Rapid offset may leave patient in pain if transitional analgesia inadequate [1]
• OIH risk with higher doses may increase postoperative pain [1]

My preferred approach: [4 marks]

"I would use remifentanil-based TIVA with a comprehensive multimodal analgesia plan:"

• Remifentanil 0.1-0.2 mcg/kg/min with propofol TCI (avoiding excessive remifentanil doses) [1]
• Pre-operative: paracetamol 1g, parecoxib 40mg IV [1]
• Intraoperative: local anesthetic port site infiltration, consider rectus sheath block [1]
• Transitional: morphine 5-10 mg IV 20-30 minutes before emergence [1]

Addressing patient anxiety: [2 marks]

• Explain analgesic plan preoperatively to reduce anxiety [1]
• Ensure PCA available in recovery if needed, with clear escalation plan [1]

Evidence base: [2 marks]

• TIVA reduces PONV which improves day surgery discharge [1]
• Multimodal approach reduces opioid requirements and OIH risk [1]

Total: 15 marks

---

References

1. Egan TD, Lemmens HJ, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology. 1993;79(5):881-892. PMID: 7902033
2. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology. 1993;79(5):893-903. PMID: 7902034
3. Glass PS, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth Analg. 1993;77(5):1031-1040. PMID: 8105723
4. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997;86(1):10-23. PMID: 9009935
5. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology. 1997;86(1):24-33. PMID: 9009936
6. Burkle H, Dunbar S, Van Aken H. Remifentanil: a novel, short-acting, mu-opioid. Anesth Analg. 1996;83(3):646-651. PMID: 8780298
7. Thompson JP, Rowbotham DJ. Remifentanil - an opioid for the 21st century. Br J Anaesth. 1996;76(3):341-343. PMID: 8785129
8. Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on remifentanil. Crit Care. 2008;12(Suppl 3):S5. PMID: 18495056
9. Kapila A, Glass PS, Jacobs JR, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology. 1995;83(5):968-975. PMID: 7486182
10. Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology. 1992;76(3):334-341. PMID: 1539843
11. Egan TD. Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Clin Pharmacokinet. 1995;29(2):80-94. PMID: 7586904
12. Hoke JF, Cunningham F, James MK, et al. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther. 1997;281(1):226-232. PMID: 9103503
13. Patel SS, Spencer CM. Remifentanil. Drugs. 1996;52(3):417-427. PMID: 8875131
14. Selinger K, Lanzo C, Engel J. Determination of remifentanil in human and dog blood by HPLC with UV detection. J Pharm Biomed Anal. 1994;12(2):243-248. PMID: 8003553
15. Thompson JP, Hall AP, Russell J, et al. Effect of remifentanil on the haemodynamic response to orotracheal intubation. Br J Anaesth. 1998;80(4):467-469. PMID: 9640151
16. Coda BA, Brown MC, Schaffer R, et al. Pharmacology of epidural fentanyl, alfentanil, and sufentanil in volunteers. Anesthesiology. 1994;81(5):1149-1161. PMID: 7978473
17. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology. 1996;84(4):812-820. PMID: 8638834
18. Hoke JF, Shlugman D, Dershwitz M, et al. Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology. 1997;87(3):533-541. PMID: 9316957
19. Davis PJ, Wilson AS, Siewers RD, et al. The effects of cardiopulmonary bypass on remifentanil kinetics in children undergoing atrial septal defect repair. Anesth Analg. 1999;89(4):904-908. PMID: 10512262
20. Pitsiu M, Wilmer A, Bodenham A, et al. Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. Br J Anaesth. 2004;92(4):493-503. PMID: 14766713
21. Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003;106(1-2):49-57. PMID: 14581110
22. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93(2):409-417. PMID: 10910490
23. Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanil infusion in humans. Anesth Analg. 1998;86(6):1307-1311. PMID: 9620525
24. Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. Br J Anaesth. 2014;112(6):991-1004. PMID: 24829420
25. Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161. PMID: 21412369
26. Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005;103(1):147-155. PMID: 15983467
27. Koppert W, Sittl R, Scheuber K, et al. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003;99(1):152-159. PMID: 12826855
28. Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133-153. PMID: 18443637
29. Ross JR, Riley J, Quigley C, et al. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006;11(7):765-773. PMID: 16880235
30. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613-624. PMID: 19567715
31. Servin FS, Billard V. Remifentanil and other opioids. Handb Exp Pharmacol. 2008;(182):283-311. PMID: 18175097
32. Scott LJ, Perry CM. Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-1823. PMID: 16114980

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols.